TRACON PHARMACEUTICALS INC (TCON) Fundamental Analysis & Valuation

NASDAQ:TCON • US89237H3084

Current stock price

1.43 USD
-0.02 (-1.38%)
At close:
1.08 USD
-0.35 (-24.48%)
After Hours:

This TCON fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. TCON Profitability Analysis

1.1 Basic Checks

  • TCON had positive earnings in the past year.
  • In the past year TCON had a positive cash flow from operations.
  • In the past 5 years TCON always reported negative net income.
  • TCON had negative operating cash flow in 4 of the past 5 years.
TCON Yearly Net Income VS EBIT VS OCF VS FCFTCON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

  • TCON's Return On Assets of 18.69% is amongst the best of the industry. TCON outperforms 99.13% of its industry peers.
Industry RankSector Rank
ROA 18.69%
ROE N/A
ROIC N/A
ROA(3y)-97.7%
ROA(5y)-92.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCON Yearly ROA, ROE, ROICTCON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 2K 4K 6K

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.39%, TCON belongs to the top of the industry, outperforming 97.04% of the companies in the same industry.
  • The Operating Margin and Gross Margin are not available for TCON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 14.39%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCON Yearly Profit, Operating, Gross MarginsTCON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. TCON Health Analysis

2.1 Basic Checks

  • TCON does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TCON has more shares outstanding
  • There is no outstanding debt for TCON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TCON Yearly Shares OutstandingTCON Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
TCON Yearly Total Debt VS Total AssetsTCON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -36.21, we must say that TCON is in the distress zone and has some risk of bankruptcy.
  • TCON has a Altman-Z score of -36.21. This is amonst the worse of the industry: TCON underperforms 93.03% of its industry peers.
  • TCON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Altman-Z -36.21
ROIC/WACCN/A
WACC74.74%
TCON Yearly LT Debt VS Equity VS FCFTCON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • A Current Ratio of 0.80 indicates that TCON may have some problems paying its short term obligations.
  • TCON has a worse Current ratio (0.80) than 90.59% of its industry peers.
  • A Quick Ratio of 0.80 indicates that TCON may have some problems paying its short term obligations.
  • TCON's Quick ratio of 0.80 is on the low side compared to the rest of the industry. TCON is outperformed by 90.07% of its industry peers.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.8
TCON Yearly Current Assets VS Current LiabilitesTCON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. TCON Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 808.59% over the past year.
  • The Revenue has been growing by 32.05% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)808.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-269.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y32.05%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -15.22% on average over the next years. This is quite bad
  • TCON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.68% yearly.
EPS Next Y-142.4%
EPS Next 2Y-51.36%
EPS Next 3Y-84.04%
EPS Next 5Y-15.22%
Revenue Next Year-100%
Revenue Next 2Y-66.67%
Revenue Next 3Y32.08%
Revenue Next 5Y63.68%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TCON Yearly Revenue VS EstimatesTCON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2023 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
TCON Yearly EPS VS EstimatesTCON Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 10 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

4

4. TCON Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 0.16, the valuation of TCON can be described as very cheap.
  • TCON's Price/Earnings ratio is rather cheap when compared to the industry. TCON is cheaper than 100.00% of the companies in the same industry.
  • TCON is valuated cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
  • The Forward Price/Earnings Ratio is negative for TCON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0.16
Fwd PE N/A
TCON Price Earnings VS Forward Price EarningsTCON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

  • 100.00% of the companies in the same industry are more expensive than TCON, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 0.62
EV/EBITDA N/A
TCON Per share dataTCON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • TCON's earnings are expected to decrease with -84.04% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-51.36%
EPS Next 3Y-84.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TCON Dividend Analysis

5.1 Amount

  • No dividends for TCON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

TCON Fundamentals: All Metrics, Ratios and Statistics

TRACON PHARMACEUTICALS INC

NASDAQ:TCON (6/27/2024, 7:53:15 PM)

After market: 1.08 -0.35 (-24.48%)

1.43

-0.02 (-1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14
Earnings (Next)08-12
Inst Owners9.71%
Inst Owner Change0%
Ins Owners214.98%
Ins Owner Change0%
Market Cap3.83M
Revenue(TTM)12.14M
Net Income(TTM)1.75M
Analysts80
Price Target31.11 (2075.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)51.34%
Min EPS beat(2)-9.57%
Max EPS beat(2)112.26%
EPS beat(4)3
Avg EPS beat(4)238.94%
Min EPS beat(4)-9.57%
Max EPS beat(4)537.41%
EPS beat(8)4
Avg EPS beat(8)115.22%
EPS beat(12)4
Avg EPS beat(12)66.7%
EPS beat(16)7
Avg EPS beat(16)54.23%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)771.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2457.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-943.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.16
Fwd PE N/A
P/S 0.32
P/FCF 0.62
P/OCF 0.62
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)9.07
EY634.27%
EPS(NY)-2.92
Fwd EYN/A
FCF(TTM)2.29
FCFY160.11%
OCF(TTM)2.29
OCFY160.11%
SpS4.53
BVpS-0.66
TBVpS-0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 18.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14.39%
GM N/A
FCFM 50.52%
ROA(3y)-97.7%
ROA(5y)-92.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover1.3
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 351.03%
Current Ratio 0.8
Quick Ratio 0.8
Altman-Z -36.21
F-Score8
WACC74.74%
ROIC/WACCN/A
Cap/Depr(3y)149.7%
Cap/Depr(5y)98.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)808.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-269.44%
EPS Next Y-142.4%
EPS Next 2Y-51.36%
EPS Next 3Y-84.04%
EPS Next 5Y-15.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y32.05%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-66.67%
Revenue Next 3Y32.08%
Revenue Next 5Y63.68%
EBIT growth 1Y89.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y125.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.09%
OCF growth 3YN/A
OCF growth 5YN/A

TRACON PHARMACEUTICALS INC / TCON Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TRACON PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 4 / 10 to TCON.


What is the valuation status for TCON stock?

ChartMill assigns a valuation rating of 4 / 10 to TRACON PHARMACEUTICALS INC (TCON). This can be considered as Fairly Valued.


Can you provide the profitability details for TRACON PHARMACEUTICALS INC?

TRACON PHARMACEUTICALS INC (TCON) has a profitability rating of 2 / 10.


What is the valuation of TRACON PHARMACEUTICALS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TRACON PHARMACEUTICALS INC (TCON) is 0.16 and the Price/Book (PB) ratio is -2.18.


Can you provide the expected EPS growth for TCON stock?

The Earnings per Share (EPS) of TRACON PHARMACEUTICALS INC (TCON) is expected to decline by -142.4% in the next year.